December 2016
-
Robert Clarke is stepping down as CEO of DPI developer Pulmatrix and will be succeeded immediately by current Chief Business Officer Ted Raad, the company said. Clarke, who was appointed CEO in 2012, will stay… Read more . . .
-
Pneuma Respiratory has announced a licensing agreement with Nanjing Leads Biolabs subsidiary Leads Biolabs, Inc. for rights to develop Leads monoclonal antibodies and fusion protein molecules for delivery using Pneuma’s digital soft mist inhaler. Pneuma… Read more . . .
-
Etripamil developer Milestone Pharmaceuticals announced that its recently closed initial public offering raised approximately $82.5 million gross by selling 5,500,000 common shares at $15/share. The company is developing intranasal etripamil for the treatment of paroxysmal… Read more . . .
-
Glenmark Pharmaceuticals recently said that a Phase 3 study comparing Ryaltris olopatadine hydrochloride to placebo in seasonal allergic rhinitis patients aged 6 up to 12 years achieved its primary endpoint. The 14-day study, which enrolled… Read more . . .
-
The FDA’s Pulmonary‐Allergy Drugs Advisory Committee (PADAC) has voted to recommend approval of Chiesi’s NDA for Bronchitol DPI for the treatment of cystic fibrosis in adult patients. According to Bronchitol developer Pharmaxis, Chiesi re-submitted the… Read more . . .
-
Recipharm has announced the launch of an integrated OINDP services program called Inhalation Solutions which covers development of MDIs, DPIs, and nasal sprays from early analytical services to scale up and commercial manufacturing. In June… Read more . . .
-
Verona Pharma said that it has initiated a Phase 2b dose-ranging study of RPL554 nebulized ensifentrine for the treatment of COPD, with results expected by the end of 2019. The company, which reported positive results… Read more . . .
-
According to Vectura, a jury has found that US sales of several of GlaxoSmithKline’s Ellipta DPIs infringed on Vectura’s US patent 8303991 (“Method of making particles for use in a pharmaceutical composition”). The jury awarded… Read more . . .
-
GlaxoSmithKline and Innoviva have announced that the Phase 3 CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study comparing the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI to the Relvar/Breo Ellipta… Read more . . .
-
Submit abstracts for oral and poster presentations by 12 July 2019 at https://aerosol-soc.com/abstract-submission/ Abstract guidelines can be found at https://aerosol-soc.com/assets/uploads/2018/12/DDL-Abstract-Guidelines-2019-1.docx Themes for DDL2019 are: FUTURE OF THE PLANET: Pollution and the environment FUTURE PREDICTIONS: Patients and Personalisation… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland